Surgical Science (Buy, TP: SEK225.00) - Mixed Q2 report; solid growth outlook
A mixed Q2 report, with sales in line but adj. EBIT below our estimate, was largely due to a one-off effect and slightly lower activity in Industry/OEM. We have lowered our 2024–2026 estimates slightly, but a strong outlook for H2 and 2025 means we reiterate our BUY and SEK225 target price. We believe the current weak share price presents an opportunity for long-term investors.
DNB Markets is the investment banking arm of DNB Bank ASA and is focused primarily on the Nordic region, as well as internationally on niches such as global shipping, energy and related services, and seafood. DNB Markets offers services in FICC, Equities and Investment Banking advisory from offices in Oslo, Stockholm, London, Singapore and New York. Equity research coverage is offered on c250 Nordic companies. DNB was ranked no.2 in Extel Nordic Research 2017. The DNB Markets’ Credit and FICC Macro & FX Research teams are repeatedly highly rated by Prospera Nordic Institutional Investor Surveys.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.